A Case of Posterior Reversible Encephalopathy Syndrome Associated With Pembrolizumab and Cetuximab Combination Therapy.

Posterior reversible encephalopathy syndrome (PRES) is a neurologic condition with a constellation of symptoms, including altered mentation, headaches, and often seizures. Immunosuppressive therapies and, more recently, immunotherapy have been identified as risk factors for PRES. We describe the first documented case of PRES associated with a combination of pembrolizumab and cetuximab therapy. This case presentation aims to highlight a rare but potential adverse effect associated with immunotherapy. Awareness of this association and early recognition of symptoms can lead to prompt management and resolution of PRES. Further research is needed to elucidate the mechanisms and risk factors contributing to PRES.
Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
(Copyright © 2024, Patel et al.)